The Technical AnalystExchange: ASX Industry: Health Care Equipment & Services
Neurotech International Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0910
America/New_York / 2 mai 2024 @ 02:10
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 92.58 mill |
| EPS: | -0.0100 |
| P/E: | -9.10 |
| Earnings Date: | Feb 27, 2024 |
| SharesOutstanding: | 1 017.39 mill |
| Avg Daily Volume: | 2.12 mill |
| RATING 2024-05-02 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.10 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.17x |
| Company: PE -9.10 | industry: PE 54.21 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0038 (-95.88%) $-0.0872 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0840 - 0.0980 ( +/- 7.69%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0910 (0.00% ) |
| Volume | 0.564 mill |
| Avg. Vol. | 2.12 mill |
| % of Avg. Vol | 26.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NTI.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NTI.AX
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.